Lakewood — Amedex wins IRB approval for Phase 2a Nu — 3 diabetic foot ulcer trial
Lakewood-Amedex won central IRB clearance for its Phase 2a Nu-3 trial in mildly infected diabetic foot ulcers. All participating sites also secured IRB sign-off, clearing the way to start patient enrollment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence.